Prospective Validation and Refinement of a Population Pharmacokinetic Model of Fludarabine in Children and Young Adults Undergoing Hematopoietic Cell Transplantation (original) (raw)

Abstract

Fludarabine is a nucleoside analog with antileukemic and immunosuppressive activity commonly used in allogeneic hematopoietic cell transplantation (HCT). Several fludarabine population pharmacokinetic (popPK) and pharmacodynamic models have been published enabling the movement towards precision dosing of fludarabine in pediatric HCT; however, developed models have not been validated in a prospective cohort of patients. In this multicenter pharmacokinetic study, fludarabine plasma concentrations were collected via a sparse-sampling strategy. A fludarabine popPK model was evaluated and refined using standard nonlinear mixed effects modelling techniques. The previously described fludarabine popPK model well-predicted the prospective fludarabine plasma concentrations. Individuals who received model-based dosing (MBD) of fludarabine achieved significantly more precise overall exposure of fludarabine. The fludarabine popPK model was further improved by both the inclusion of fat-free mass ...

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (14)

  1. Annaloro, C.; Costa, A.; Fracchiolla, N.S.; Mometto, G.; Artuso, S.; Saporiti, G.; Tagliaferri, E.; Grifoni, F.; Onida, F.; Cortelezzi, A. Severe fludarabine neurotoxicity after reduced intensity conditioning regimen to allogeneic hematopoietic stem cell trans- plantation: A case report. Clin. Case Rep. 2015, 3, 650-655. https://doi.org/10.1002/ccr3.308.
  2. Annaloro, C.; Costa, A.; Fracchiolla, N.S.; Mometto, G.; Artuso, S.; Saporiti, G.; Tagliaferri, E.; Grifoni, F.; Onida, F.; Cortelezzi, A. Severe fludarabine neurotoxicity after reduced intensity conditioning regimen to allogeneic hematopoietic stem cell transplanta- tion: A case report. Clin. Case Rep. 2015, 3, 650-655. [CrossRef] [PubMed]
  3. Avramis, V.I.; Wiersma, S.; Krailo, M.D.; Ramilo-Torno, L.V.; Sharpe, A.; Liu-Mares, W.; Kowck, R.; Reaman, G.H.; Sato, J.K. Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group. Clin. Cancer Res. 1998, 4, 45-52. [PubMed]
  4. Avramis, V.I.; Champagne, J.; Sato, J.; Krailo, M.; Ettinger, L.J.; Poplack, D.G.; Finkelstein, J.; Reaman, G.; Hammond, G.D.; Holcenberg, J.S. Pharmacology of fludarabine phosphate after a phase I/II trial by a loading bolus and continuous infusion in pediatric patients. Cancer Res. 1990, 50, 7226-7231. [PubMed]
  5. Salinger, D.H.; Blough, D.K.; Vicini, P.; Anasetti, C.; O'Donnell, P.V.; Sandmaier, B.M.; McCune, J.S. A Limited Sampling Schedule to Estimate Individual Pharmacokinetic Parameters of Fludarabine in Hematopoietic Cell Transplant Patients. Clin. Cancer Res. 2009, 15, 5280-5287. [CrossRef] [PubMed]
  6. Long-Boyle, J.R.; Green, K.G.; Brunstein, C.G.; Cao, Q.; Rogosheske, J.; Weisdorf, D.J.; Miller, J.S.; Wagner, J.E.; McGlave, P.B.; Jacobson, P.A. High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation. Bone Marrow Transplant. 2011, 46, 20-26. [CrossRef] [PubMed]
  7. Bornhäuser, M.; Storer, B.; Slattery, J.T.; Appelbaum, F.R.; Deeg, H.J.; Hansen, J.; Martin, P.J.; McDonald, G.B.; Nichols, W.G.; Radich, J.; et al. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood 2003, 102, 820-826. [CrossRef] [PubMed]
  8. Langenhorst, J.B.; Dorlo, T.P.C.; van Maarseveen, E.M.; Nierkens, S.; Kuball, J.; Boelens, J.J.; van Kesteren, C.; Huitema, A.D.R. Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation. Clin. Pharmacokinet. 2019, 58, 627-637. [CrossRef] [PubMed]
  9. Ivaturi, V.; Dvorak, C.C.; Chan, D.; Liu, T.; Cowan, M.J.; Wahlstrom, J.; Stricherz, M.; Jennissen, C.; Orchard, P.J.; Tolar, J.; et al. Pharmacokinetics and Model-Based Dosing to Optimize Fludarabine Therapy in Pediatric Hematopoietic Cell Transplant Recipients. Biol. Blood Marrow Transplant. 2017, 23, 1701-1713. [CrossRef] [PubMed]
  10. Langenhorst, J.B.; Van Kesteren, C.; Van Maarseveen, E.M.; Dorlo, T.P.C.; Nierkens, S.; Lindemans, C.A.; De Witte, M.A.; Van Rhenen, A.; Raijmakers, R.; Bierings, M.; et al. Fludarabine exposure in the conditioning prior to allogeneic hematopoietic cell transplantation predicts outcomes. Blood Adv. 2019, 3, 2179-2187. [CrossRef] [PubMed]
  11. Al-Sallami, H.S.; Goulding, A.; Grant, A.; Taylor, R.; Holford, N.; Duffull, S.B. Prediction of Fat-Free Mass in Children. Clin. Pharmacokinet. 2015, 54, 1169-1178. [CrossRef] [PubMed]
  12. Huang, L.; Lizak, P.; Dvorak, C.C.; Aweeka, F.; Long-Boyle, J. Simultaneous determination of fludarabine and clofarabine in human plasma by LC-MS/MS. J. Chromatogr. B 2014, 960, 194-199. [CrossRef] [PubMed]
  13. Clinical Growth Charts. Available online: https://www.cdc.gov/growthcharts/clinical\_charts.htm (accessed on 8 August 2022).
  14. Kearns, G.L.; Abdel-Rahman, S.M.; Alander, S.W.; Blowey, D.L.; Leeder, J.S.; Kauffman, R.E. Developmental Pharmacology-Drug Disposition, Action, and Therapy in Infants and Children. N. Engl. J. Med. 2003, 349, 1157-1167. [CrossRef] [PubMed]